Direkt zum Inhalt

Gunawan, Stefan ; Elger, Tanja ; Loibl, Johanna ; Fererberger, Tanja ; Sommersberger, Stefanie ; Kandulski, Arne ; Müller-Schilling, Martina ; Tews, Hauke Christian ; Buechler, Christa

Urinary chemerin as a potential biomarker for inflammatory bowel disease

Gunawan, Stefan, Elger, Tanja, Loibl, Johanna, Fererberger, Tanja, Sommersberger, Stefanie, Kandulski, Arne, Müller-Schilling, Martina, Tews, Hauke Christian und Buechler, Christa (2022) Urinary chemerin as a potential biomarker for inflammatory bowel disease. Frontiers in Medicine 9.

Veröffentlichungsdatum dieses Volltextes: 18 Jan 2023 11:59
Artikel
DOI zum Zitieren dieses Dokuments: 10.5283/epub.53561


Zusammenfassung

PurposeSystemic levels of the adipokine chemerin are elevated in different inflammatory conditions such as inflammatory bowel disease (IBD). In IBD, chemerin protein expression in colon mucosa is induced and serum chemerin levels are increased. Aim of this study was to identify chemerin protein in human feces and/or urine and to evaluate a possible association with IBD activity. Materials and ...

PurposeSystemic levels of the adipokine chemerin are elevated in different inflammatory conditions such as inflammatory bowel disease (IBD). In IBD, chemerin protein expression in colon mucosa is induced and serum chemerin levels are increased. Aim of this study was to identify chemerin protein in human feces and/or urine and to evaluate a possible association with IBD activity. Materials and methodsFeces and urine of 40 patients with IBD and the respective sera of 34 patients were collected. Chemerin levels were analyzed by immunoblot in feces and urine samples. In addition, enzyme-linked immunosorbent assay (ELISA) was used to measure chemerin in all urine, feces and serum samples of the patients and in urine of 17 healthy controls. ResultsChemerin was not detectable in 80% of the human feces samples by ELISA. Chemerin in human urine was detected by immunoblot and ELISA. Compared to serum levels, urinary concentration was about 6,000-fold lower. Urinary chemerin did not differ between patients with ulcerative colitis (n = 15) and Crohn's disease (n = 25). Urinary chemerin was not related to its serum levels, did not correlate with serum C-reactive protein level and negatively correlated with serum creatinine. Of note, urinary chemerin of patients with a fecal calprotectin > 500 mu g/g was significantly higher compared to patients with lower calprotectin levels and compared to healthy controls. Serum creatinine did not differ between the patient groups. ConclusionUrinary chemerin might present a novel non-invasive biomarker for monitoring IBD severity and clinical course.



Beteiligte Einrichtungen


Details

DokumentenartArtikel
Titel eines Journals oder einer ZeitschriftFrontiers in Medicine
Verlag:Frontiers
Ort der Veröffentlichung:LAUSANNE
Band:9
Datum10 November 2022
InstitutionenMedizin > Lehrstuhl für Innere Medizin I
Identifikationsnummer
WertTyp
10.3389/fmed.2022.1058108DOI
Stichwörter / KeywordsFECAL CALPROTECTIN; ULCERATIVE-COLITIS; SERUM CHEMERIN; ASSOCIATION; PROTEIN; OBESE; urine biomarker; feces; calprotectin; creatinine; C-reactive protein; Crohn's disease; ulcerative colitis; inflammatory bowel disease (IBD)
Dewey-Dezimal-Klassifikation600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin
StatusVeröffentlicht
BegutachtetJa, diese Version wurde begutachtet
An der Universität Regensburg entstandenJa
URN der UB Regensburgurn:nbn:de:bvb:355-epub-535610
Dokumenten-ID53561

Bibliographische Daten exportieren

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

nach oben